



## Dr. Isabelle LORDEREAU, Amgen

Isabelle Lordereau is a MD and a pediatric endocrinologist by training in Paris hospitals where she served as Senior Resident. In fundamental research she obtained a master in immunology and molecular biology and conducted a research program on IGF1 liaison proteins.

She moved to Pharma Industry in 1993 and served Sanofi France, Sanofi Global, Servier R&D, GSK Europe, GSK International, BMS Europe and BMS Global. She worked in close partnership with Pfizer, AZ and Medtronic.

Isabelle has developed and overseen launch and growth of important drugs in the CV field (clopidogrel, fondaparinux, apixaban and evolocumab). She has established trusty relationships with number of Scientific Societies and their boards: ESC, ACCP, AHA and ACC members as well as PHRI, TIMI and Cardiolytic groups. She worked in teams to obtain approval from EMA, FDA and WHO as well as reimbursement from HTA bodies in Europe.

In 2012 she received the French Honors from the French Ministry of Industry for her research and dedication into Innovation in the Cardiovascular field as she was responsible for the launch of ELIQUIS in Europe.

Isabelle joined Amgen Europe in 2018 and moved to a Global Executive Leader position in 2020.

She is currently Executive Medical Director and Global Disease Area Head Bone Neurology Nephrology. She serves a company dedicated to innovation with a unique pipeline in CV, inflammation, rare diseases and oncology. Amgen long-term vision (2030) is to bring extraordinary medicines to patients with very high unmet needs in the context of precision medicine.

Between 2020 and 2023, Isabelle was elected by her Industry Peers and served as ESC CRT Co-Chair. In this role she developed with the ESC Elect-Presidents several CRT programs and publications in collaboration with Industry and EMA in Lipids management, Elderly management, RWE, Digital CV and precision medicine. She is currently a member of the ESC CRT Nucleus